{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:41:14Z","timestamp":1789760474930,"version":"4.0.1"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1001\/jamacardio.2018.0653","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T12:32:10Z","timestamp":1524054730000},"page":"473","source":"Crossref","is-referenced-by-count":44,"title":["Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome"],"prefix":"10.1001","volume":"3","author":[{"given":"Brian A.","family":"Bergmark","sequence":"first","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob A.","family":"Udell","sequence":"additional","affiliation":[{"name":"Department of Medicine, Women\u2019s College Hospital and the University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Baim Institute, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan L.","family":"Steen","sequence":"additional","affiliation":[{"name":"Cardiovascular Health and Disease Division, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Jarolim","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Budaj","sequence":"additional","affiliation":[{"name":"Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hamm","sequence":"additional","affiliation":[{"name":"Kerckhoff Heart Center, Bad Nauheim, University of Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Guo","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KyungAh","family":"Im","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia F.","family":"Kuder","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Deputy Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[{"name":"Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"hoi180015r1","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1681\/ASN.2007010068","article-title":"How fibroblast growth factor 23 works.","volume":"18","author":"Liu","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"hoi180015r2","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/ndt\/gfp699","article-title":"Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study.","volume":"25","author":"Ix","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"19","key":"hoi180015r3","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.","volume":"119","author":"Guti\u00e9rrez","year":"2009","journal-title":"Circulation"},{"issue":"12","key":"hoi180015r4","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1253\/circj.CJ-10-0355","article-title":"Association between fibroblast growth factor 23 and left ventricular hypertrophy in maintenance hemodialysis patients: comparison with B-type natriuretic peptide and cardiac troponin T.","volume":"74","author":"Negishi","year":"2010","journal-title":"Circ J"},{"issue":"11","key":"hoi180015r5","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy.","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"issue":"8","key":"hoi180015r6","doi-asserted-by":"publisher","first-page":"E863","DOI":"10.1152\/ajpendo.00596.2012","article-title":"FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.","volume":"304","author":"Touchberry","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"hoi180015r7","doi-asserted-by":"publisher","first-page":"e44161","DOI":"10.1371\/journal.pone.0044161","article-title":"A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model.","volume":"7","author":"Dai","year":"2012","journal-title":"PLoS One"},{"issue":"18","key":"hoi180015r8","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.111.053405","article-title":"Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23.","volume":"125","author":"Lim","year":"2012","journal-title":"Circulation"},{"key":"hoi180015r9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ijcard.2016.07.276","article-title":"Elevated fibroblast growth factor-23 and risk of cardiovascular disease or mortality in the general population: a meta-analysis.","volume":"222","author":"Jiang","year":"2016","journal-title":"Int J Cardiol"},{"issue":"3","key":"hoi180015r10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).","volume":"60","author":"Ix","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi180015r11","doi-asserted-by":"publisher","first-page":"e000936, 000931","DOI":"10.1161\/JAHA.114.000936","article-title":"Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the atherosclerosis risk in communities study.","volume":"3","author":"Lutsey","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"hoi180015r12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi180015r13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2013050465","article-title":"Fibroblast growth factor-23 and cardiovascular events in CKD.","volume":"25","author":"Scialla","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"hoi180015r14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/dmrr.v32.7","article-title":"Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease.","volume":"32","author":"Tu\u00f1\u00f3n","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"issue":"21","key":"hoi180015r15","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1093\/eurheartj\/ehr215","article-title":"The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.","volume":"32","author":"Seiler","year":"2011","journal-title":"Eur Heart J"},{"issue":"22","key":"hoi180015r16","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1016\/j.jacc.2014.03.026","article-title":"Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.","volume":"63","author":"Udell","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"hoi180015r17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","article-title":"Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial [published correction appears in JAMA. 2014;312(14):1473].","volume":"312","author":"O\u2019Donoghue","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"hoi180015r19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ahj.2011.07.018","article-title":"Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.","volume":"162","author":"O\u2019Donoghue","year":"2011","journal-title":"Am Heart J"},{"issue":"20","key":"hoi180015r20","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"17","key":"hoi180015r21","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi180015r22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Index for rating diagnostic tests.","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"issue":"9","key":"hoi180015r23","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/sim.5727","article-title":"Testing for improvement in prediction model performance.","volume":"32","author":"Pepe","year":"2013","journal-title":"Stat Med"},{"issue":"1","key":"hoi180015r24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ki.2012.327","article-title":"Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community.","volume":"83","author":"\u00c4rnl\u00f6v","year":"2013","journal-title":"Kidney Int"},{"issue":"7","key":"hoi180015r25","doi-asserted-by":"publisher","first-page":"e003486, 003481","DOI":"10.1161\/JAHA.116.003486","article-title":"Plasma fibroblast growth factor 23: clinical correlates and association with cardiovascular disease and mortality in the Framingham Heart Study.","volume":"5","author":"Haring","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"hoi180015r26","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1161\/CIRCHEARTFAILURE.115.002341","article-title":"Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fraction.","volume":"8","author":"Koller","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"10","key":"hoi180015r27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jchf.2015.05.012","article-title":"Association of fibroblast growth factor-23 levels and angiotensin-converting enzyme inhibition in chronic systolic heart failure.","volume":"3","author":"Wohlfahrt","year":"2015","journal-title":"JACC Heart Fail"},{"issue":"18","key":"hoi180015r28","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1161\/CIRCULATIONAHA.112.104828","article-title":"Klotho: a master regulator of cardiovascular disease?","volume":"125","author":"Moe","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"hoi180015r29","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1161\/01.HYP.0000013734.33441.EA","article-title":"In vivo klotho gene transfer ameliorates angiotensin II\u2013induced renal damage.","volume":"39","author":"Mitani","year":"2002","journal-title":"Hypertension"},{"issue":"2","key":"hoi180015r30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.bbrc.2016.03.029","article-title":"Klotho inhibits angiotensin II-induced cardiomyocyte hypertrophy through suppression of the AT1R\/beta catenin pathway.","volume":"473","author":"Yu","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"22","key":"hoi180015r31","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1056\/NEJMcibr022472","article-title":"Angiotensin-converting enzyme 2\u2014a new cardiac regulator.","volume":"347","author":"Boehm","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"hoi180015r32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1161\/CIRCHEARTFAILURE.113.000952","article-title":"Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis.","volume":"7","author":"Kestenbaum","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"11","key":"hoi180015r33","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1093\/ndt\/gfu190","article-title":"Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.","volume":"29","author":"Di Marco","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"hoi180015r34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, FGF23 and cardiovascular disease in hemodialysis: the EVOLVE trial.","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"hoi180015r35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1681\/ASN.2009121311","article-title":"Klotho deficiency causes vascular calcification in chronic kidney disease.","volume":"22","author":"Hu","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"hoi180015r36","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1172\/JCI200419081","article-title":"Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.","volume":"113","author":"Shimada","year":"2004","journal-title":"J Clin Invest"},{"issue":"4","key":"hoi180015r37","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/MNH.0000000000000231","article-title":"The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.","volume":"25","author":"Grabner","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"hoi180015r38","doi-asserted-by":"publisher","first-page":"e95402","DOI":"10.1371\/journal.pone.0095402","article-title":"Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease.","volume":"9","author":"Tu\u00f1\u00f3n","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"hoi180015r39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1053\/j.ajkd.2015.06.027","article-title":"Sex, age, and the association of serum phosphorus with all-cause mortality in adults with normal kidney function.","volume":"67","author":"Yoo","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"hoi180015r40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1053\/j.ajkd.2011.06.011","article-title":"Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study.","volume":"58","author":"Ix","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"hoi180015r18","unstructured":"Clinicaltrials.gov. The Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 Trial. NCT01000727. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01000727.Accessed October 1, 2017."}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2678663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:25:11Z","timestamp":1571185511000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2018.0653"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2018.0653","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}